中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2013年
30期
3-4
,共2页
促红细胞生成素%肿瘤%贫血%化疗
促紅細胞生成素%腫瘤%貧血%化療
촉홍세포생성소%종류%빈혈%화료
Hemopoietin%Tumor%Anemia%Chemotherapy
目的:探讨促红细胞生成素对肿瘤性贫血的临床治疗效果。方法:选取肺癌患者70例,随机分为实验组与对照组,每组35例,实验组患者在采用化疗治疗的基础上,加以1000单位/次,皮下注射促红细胞生成素,1周2次;对照组患者采用常规化疗。治疗8周后,观察两组患者治疗前后的血红蛋白(Hb)、红细胞比容(HCT)、网织红细胞百分数(RET%),并观察患者有无药物治疗反应。结果:治疗8周后,实验组的Hb平均值为(110.1±6.8)g/L,HCT平均值为(35.8±3.7)Vol%,RET的平均值为(1.76±0.07)%,均较治疗前明显升高(P<0.05);对照组患者的Hb平均值为(78.4±5.6)g/L,HCT平均值为(19.7±3.7)Vol%,RET的平均值为(0.91±0.06)%,较治疗前无明显变化(P>0.05)。此外,实验组经治疗时未发现有明显的并发症。结论:促红细胞生成素治疗肿瘤性贫血临床效果显著,无明显毒副作用,临床上值得应用。
目的:探討促紅細胞生成素對腫瘤性貧血的臨床治療效果。方法:選取肺癌患者70例,隨機分為實驗組與對照組,每組35例,實驗組患者在採用化療治療的基礎上,加以1000單位/次,皮下註射促紅細胞生成素,1週2次;對照組患者採用常規化療。治療8週後,觀察兩組患者治療前後的血紅蛋白(Hb)、紅細胞比容(HCT)、網織紅細胞百分數(RET%),併觀察患者有無藥物治療反應。結果:治療8週後,實驗組的Hb平均值為(110.1±6.8)g/L,HCT平均值為(35.8±3.7)Vol%,RET的平均值為(1.76±0.07)%,均較治療前明顯升高(P<0.05);對照組患者的Hb平均值為(78.4±5.6)g/L,HCT平均值為(19.7±3.7)Vol%,RET的平均值為(0.91±0.06)%,較治療前無明顯變化(P>0.05)。此外,實驗組經治療時未髮現有明顯的併髮癥。結論:促紅細胞生成素治療腫瘤性貧血臨床效果顯著,無明顯毒副作用,臨床上值得應用。
목적:탐토촉홍세포생성소대종류성빈혈적림상치료효과。방법:선취폐암환자70례,수궤분위실험조여대조조,매조35례,실험조환자재채용화료치료적기출상,가이1000단위/차,피하주사촉홍세포생성소,1주2차;대조조환자채용상규화료。치료8주후,관찰량조환자치료전후적혈홍단백(Hb)、홍세포비용(HCT)、망직홍세포백분수(RET%),병관찰환자유무약물치료반응。결과:치료8주후,실험조적Hb평균치위(110.1±6.8)g/L,HCT평균치위(35.8±3.7)Vol%,RET적평균치위(1.76±0.07)%,균교치료전명현승고(P<0.05);대조조환자적Hb평균치위(78.4±5.6)g/L,HCT평균치위(19.7±3.7)Vol%,RET적평균치위(0.91±0.06)%,교치료전무명현변화(P>0.05)。차외,실험조경치료시미발현유명현적병발증。결론:촉홍세포생성소치료종류성빈혈림상효과현저,무명현독부작용,림상상치득응용。
Objective:To discuss hemopoietin’s clinical treatment effects on tumor anemia. Method:To choose 70 lung cancer patients,and divide them into experimental group and control group,and each group had 35 cases. To add 1000 units/time of hemopoietin subcutaneous injection to experimental group’s patients on the basis of chemotherapy,two times each week. While to adopt conventional chemotherapy to control group’s patients. After 8 weeks of treatment,to observe the two groups’ hemoglobin,hematocrit value,and reticulocyte percentage,and whether they had had drug treatment responses. Result:After 8 weeks of treatment,experimental group’s Hb average value was(110.1±6.8)g/L,HCT average value was (35.8±3.7)Vol%,RET’s was(1.76±0.07)%,these three values increased significantly when compared with before treatment(P<0.05). Control group’s Hb average value was(78.4±5.6)g/L,HCT average value was(19.7±3.7)Vol%,RET’s was(0.91±0.06)%,these three values did not obviously change compared with before treatment(P>0.05). Moreover,experimental group’s patients did not occur evident complications. Conclusion:Hemopoietin has significant clinical effect on tumor anemia,it does not have obvious toxic and side effect,and is worthy of clinical application.